Direct Oral Anticoagulants (DOACs)

 

Rivaroxaban and dabigatran are non-formulary, with the exception of rivaroxaban for thromboprophylaxis in elective hip and knee arthroplasty.

Advice for the management of patients on DOACs, including advice on the reversal of dabigatran using the antidote idarucizumab can be found using the following links:

 

Rivaroxaban for thromboprophylaxis in elective hip and knee arthroplasty:

  • A dose of 10mg once daily is started 6-10 hours after surgery, provided haemostasis has been established.
  • Treatment duration is 5 weeks for hip replacement and 2 weeks for knee replacement.
  • Any patient being discharged from hospital will be given the required amount to complete the course of treatment and the GP should not be required to prescribe rivaroxaban.